| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/24/2009 | US7507798 Antibody specific for mutant presenilin 1 |
| 03/24/2009 | US7507795 Zcytor17 ligand cytokine; immunostimulators system, and proliferation and/or development of hematopoietic cells in vitro and in vivo; transcription, gene expression, culturing; anticarcinogenic and antiinflammatory agents; diabetes, pancreatitis, inflammatory bowel disease; autoimmune diseases |
| 03/24/2009 | US7507794 Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2) |
| 03/24/2009 | US7507792 MDA-7 proteins and methods of use thereof |
| 03/24/2009 | US7507790 Plurality of peptide monomers each being attached at one end to a hub capable of interacting with a sub-unit of a self-assembling peptide to form an overlapping staggered structure or protein; purification of blood or biological fluids, cell assembly and tissue engineering |
| 03/24/2009 | US7507787 Polynucleotides; induce immunology response; antiinflammatory agents; detection polynucleotide patten |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507766 Treatment of cancers |
| 03/24/2009 | US7507745 Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| 03/24/2009 | US7507719 Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
| 03/24/2009 | US7507718 Polymyxin B analogs for LPS detoxification |
| 03/24/2009 | US7507717 Inhibitors of neuronal amine transporters of neurotransmitters, such as noradrenaline, serotonin, dopamine, glutamic acid and glycine; pain, inflammation, incontinence, cardiovascular conditions and mood disorders |
| 03/24/2009 | US7507716 Method for treating pain with prolactin antagonists |
| 03/24/2009 | US7507715 Administering parathyroid hormone and bone resorption inhibitor; bone disorders |
| 03/24/2009 | US7507714 For stimulating insulin release from pancreatic beta cells in glucose-dependent fashion; treatment of metabolic disorders such as those resulting from decreased endogenous insulin secretion, in particular type 2 diabetics, or for patients with impaired glucose tolerance |
| 03/24/2009 | US7507713 purified polypeptide and fusion protein for promoting the survival, growth, proliferation, or maintenance of neurons in an injured but not severed spinal cord; axonal regeneration, side effect reduction of scar tissue formation |
| 03/24/2009 | US7507712 NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer |
| 03/24/2009 | US7507711 A PKC V5 isozyme-specific peptide, or a modification, derivation, fragment, combination, or hybrid thereof |
| 03/24/2009 | US7507709 Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors |
| 03/24/2009 | US7507708 Particularly Kahalalide F, a tridecapeptide with a ring shape side and a lateral side amidated with 5-methylhexanoic acid; anticarcinogenic agent; refractory cancer that does not respond favorably to other treatments; peptides isolated mollusc, Elysia Elysia rufescens and its diet, a green algae |
| 03/24/2009 | US7507707 phosphodiesterase inhibitor; follicle stimulating hormone; clomiphene; anovulation disorder; collecting oocytes for in vitro fertilization; aromatase inhibitor |
| 03/24/2009 | US7507706 Administering a polypeptide to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium; IL-13 binding chains of the interleukin-13 receptor |
| 03/24/2009 | US7507705 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 03/24/2009 | US7507703 Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| 03/24/2009 | US7507580 Ztnfr14, a tumor necrosis factor receptor |
| 03/24/2009 | US7507570 Recombinant chondroitinase ABC I and uses thereof |
| 03/24/2009 | US7507556 Expresion vector comprising nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatment of cell adhesion, proliferation, inflammatory disorders; wound healing agents |
| 03/24/2009 | US7507546 Using intestinal peptide transporter (PEPT1) and/or kidney peptide transporter (PEPT2) to identify modulators which prevent transfer of sarcosine-glycine dipeptide across cells; drug delivery |
| 03/24/2009 | US7507543 GABAB receptor polypeptides and screening methods |
| 03/24/2009 | US7507542 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 03/24/2009 | US7507541 36P6D5: secreted tumor antigen |
| 03/24/2009 | US7507540 determining the presence of catalytic antibodies capable of degrading antihemophilic factors in mammals; analyzing the cleavage sites in the antihemophilic factors; biocatalysts; drugs |
| 03/24/2009 | US7507530 Nanoparticle complexes having a defined number of ligands |
| 03/24/2009 | US7507529 genetic amplification of a target nucleic acid in biological samples containing primate T-lymphotropic viruses (PTLVs), include human and simian T-lymphotropic viruses (HTLV and STLV), and detecting the strain of PTLV contained in the sample by determining nucleotide fragments that have been amplified |
| 03/24/2009 | US7507420 Peptidyl prodrugs and linkers and stabilizers useful therefor |
| 03/24/2009 | US7507419 Topically applied Clostridium botulinum toxin compositions and treatment methods |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | US7507412 for drug screening; kits for collagen and/or platelet-collagen interaction; for treatment of thrombotic and cardiovascular events and disorders |
| 03/24/2009 | US7507407 Immunoliposomes that optimize internationalization into target cells |
| 03/24/2009 | US7507404 PRO polypeptides; monoclonal/humanized antibodies; fusion proteins |
| 03/24/2009 | US7507403 drugs comprising an isolated protein, mixed with pharmaceutically acceptable carriers, excipients or diluents, used as an immunogenic composition for stimulating or enhancing the production of antibodies directed against the protein |
| 03/24/2009 | US7507401 Anti-cancer agent |
| 03/24/2009 | CA2466877C Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 03/24/2009 | CA2450690C Improved chelator conjugates |
| 03/24/2009 | CA2407715C Diagnostics and therapeutics for macular degeneration-related disorders |
| 03/24/2009 | CA2320717C Method for the treatment of diseases or disorders of the inner ear |
| 03/24/2009 | CA2136969C Prevention and treatment of peripheral neuropathy |
| 03/24/2009 | CA2087271C Superior thrombomodulin analogs for pharmaceutical use |
| 03/21/2009 | CA2602876A1 Tissue culture and cloning things |
| 03/19/2009 | WO2009036448A2 Natriuretic peptide receptor-c agonists |
| 03/19/2009 | WO2009036388A2 Gene signature for the prediction of radiation therapy response |
| 03/19/2009 | WO2009036349A1 Hsp70-based treatment for autoimmune diseases |
| 03/19/2009 | WO2009036338A2 Methods for addressing ocular diseases through interference with the wnt signaling pathway |
| 03/19/2009 | WO2009036149A2 Methods for treatment of degenerative disease associated with apoptosis |
| 03/19/2009 | WO2009036121A1 Method of inhibiting clostridium difficile by administration of oritavancin |
| 03/19/2009 | WO2009036059A2 Novel stat3 pathway inhibitors and cancer stem cell inhibitors |
| 03/19/2009 | WO2009035987A1 METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE. α-AMYLASE AND α-GLUCOSIDASE ACTIVITY IN MAMMALS |
| 03/19/2009 | WO2009035558A1 Process for the production of a crystalline glucagon receptor antagonist compound |
| 03/19/2009 | WO2009035497A2 Disease related cysteine modifications and uses thereof |
| 03/19/2009 | WO2009035460A1 Methods and compositions for treating melanoma |
| 03/19/2009 | WO2009035417A1 Neuroprotective agents |
| 03/19/2009 | WO2009035323A1 High yield secretion of multimeric recombinant protein |
| 03/19/2009 | WO2009035169A1 Peptide having anti-hypertensive activity |
| 03/19/2009 | WO2009035070A1 Transdermally absorbable preparation and transdermally absorbable system using the same |
| 03/19/2009 | WO2009035055A1 Insulin-like growth factor-1 (igf-1) production promoter |
| 03/19/2009 | WO2009034604A1 Liquid crystal emulsion-type pharmaceutical composition containing cyclosporine, and method of treating cutaneous disease therewith |
| 03/19/2009 | WO2009034452A2 Compound and device for treating bone and/or cartilage defects |
| 03/19/2009 | WO2009034134A2 Use of natriuretic peptides for treating angioedema syndromes |
| 03/19/2009 | WO2009034127A1 Use of the cyp46a1 gene for the treatment of alzheimer's disease |
| 03/19/2009 | WO2009034119A1 Improved derivatives of amylin |
| 03/19/2009 | WO2009034118A1 Stable formulations of amylin and its analogues |
| 03/19/2009 | WO2009034117A1 Mixture comprising an amylin peptide and a protracted insulin |
| 03/19/2009 | WO2009034110A1 Prevention of type 1 diabetes by administration of gliadin |
| 03/19/2009 | WO2009034041A2 Peptide sequences and compositions |
| 03/19/2009 | WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent |
| 03/19/2009 | WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent |
| 03/19/2009 | WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 03/19/2009 | WO2009033821A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids |
| 03/19/2009 | WO2009033818A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 03/19/2009 | WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 03/19/2009 | WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent |
| 03/19/2009 | WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 03/19/2009 | WO2009033813A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 03/19/2009 | WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof |
| 03/19/2009 | WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033809A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033808A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 03/19/2009 | WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 03/19/2009 | WO2009033805A2 Use of somatostatin-14 as a therapeutic agent |
| 03/19/2009 | WO2009033804A2 Use of gamma- endorphin as a therapeutic agent |
| 03/19/2009 | WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 03/19/2009 | WO2009033802A2 Antide as a therapeutic agent |
| 03/19/2009 | WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 03/19/2009 | WO2009033800A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033799A2 Use of a peptide as a therapeutic agent |